Department of Oncology, Mayo Clinic, Rochester, Minnesota.
Department of Immunology, Mayo Clinic, Rochester, Minnesota.
Clin Cancer Res. 2022 Aug 2;28(15):3173-3175. doi: 10.1158/1078-0432.CCR-22-0932.
Exploratory analysis of a phase III trial in esophageal cancer found that the patients who most contributed to an overall survival benefit from PD-1 blockade were not responders, but non-responders. The analysis has limitations but may have implications for investigating the optimal timing of immunotherapy relative to other treatments. See related article by Okada et al., p. 3277.
一项关于食管癌的 III 期临床试验的探索性分析发现，从 PD-1 阻断中获益最大的总体生存患者不是应答者，而是无应答者。该分析存在局限性，但可能对研究免疫治疗相对于其他治疗的最佳时机具有启示意义。请参阅 Okada 等人的相关文章，第 3277 页。
